Pure motor relapsing Guillain-Barré syndrome associated with anti-GM1 antibodies revealing urinary bladder cancer.
Lagrange
E
E
Veran
O
O
Besson
G
G
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001706:Biopsy; D002277:Carcinoma / Q000150:complications / Q000276:immunology*; D015653:Cystectomy; D005677:G(M1) Ganglioside / Q000276:immunology*; D020275:Guillain-Barre Syndrome / Q000276:immunology* / Q000503:physiopathology; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000276:immunology; D020361:Paraneoplastic Syndromes, Nervous System / Q000276:immunology* / Q000503:physiopathology; D010525:Peripheral Nerves / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D012008:Recurrence; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000150:complications / Q000276:immunology*
D000970:Antineoplastic Agents; D001323:Autoantibodies; D015415:Biomarkers; D005677:G(M1) Ganglioside